Immutep Limited
corporate_fare Company Profile
Immutep Limited (NASDAQ:IMMP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for IMMP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-23, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for IMMP spans 20-F, 6-K.
Recent high-impact activity:
- Immutep 20-F: A$79.3M FY26 Loss, A$68.9M Cash Into H1 2028, Audit Chair Vacancy
- Immutep Sets 1-for-20 ADS Ratio Change to Regain Nasdaq Compliance
- Immutep Pivots Efti Strategy to HNSCC and STS After TACTI-004 Root Cause Analysis
- Immutep FY26 Annual Report: A$79.3M Loss, Nasdaq Bid Price Deficiency, and Novartis Exit
- Immutep Reports A$68.9M Cash, Extends Runway to H1 2028 After TACTI-004 Wind-Down
Financial Snapshot
Short Interest & Short Volume
1.50 days to coverFINRA reported short interest of 33,547 shares in IMMP as of the October 15, 2026 settlement, a 28.3% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On October 27, 2026, 45.4% of IMMP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
IMMP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.